Biote Formalizes Commitment to Men’s Hormone Health With Launch of New Men’s Health Division
22 Junho 2023 - 8:00AM
Business Wire
Leader in Hormone Education and Training Aims
to Increase Awareness and Access to Testosterone Deficiency Therapy
through Expanded Network of Urologists and Internal Medicine
Practitioners
biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading
provider of hormone optimization, has announced the launch of a new
Men’s Health Division with the mission of redefining wellness for
men through innovation in hormone education and optimization.
Coinciding with National Men’s Health Month and headed by Biote
General Manager John Denne, this new division will focus on
increasing awareness, education and access to treatment for the
estimated 39% of men over the age of 45 who are affected by
testosterone deficiency in the United States.
“Men tend to think about health as the absence of disease and
are reluctant to ask their healthcare provider about symptoms of
low testosterone such as poor sleep, low sex drive, anxiety and
depression, and low energy,” explains Terry Weber, CEO of Biote.
“Establishing a division dedicated specifically to men was a
logical step in our commitment to increase the number of providers
in our network who are educated and trained to meet the specific
needs and preferences of male patients.”
Low testosterone, also called hypogonadism, can be detected with
a blood test and is diagnosed when a person has low testosterone
levels while also experiencing symptoms. In general, men experience
a 44% reduction of testosterone between ages 30 and 74 at the rate
of roughly 1 percent each year, unlike women who experience a
sudden drop in hormone levels at menopause. However, despite access
to care, only 12% of clinically symptomatic men are successfully
treated for low testosterone.
“When you ask a man about his cholesterol or blood pressure
level he will usually know if he is in a healthy range, but if you
ask about his hormone levels, he will likely have no idea,” says
Marc Beer, Executive Chairman of Biote. “This new division will
focus on educating and motivating men to recognize and seek
treatment for symptoms of low testosterone. At the same time, we
are providing the necessary tools and resources for urologists and
internal medicine practitioners to effectively treat these male
patients who come through the door looking for solutions.”
Roger Dmochowski, MD, MMHC, FACS and a member of the Biote
medical science advisory board, states “Ascertaining the hormonal
health of a male patient should be an essential component of any
primary care or urological examination. In addition to more obvious
symptoms, low testosterone has been associated with a wide range of
insidious health issues including cardiovascular risk and
osteoporosis.”
Biote currently trains approximately 6,400 U.S. family
practitioners, primary care practitioners and OB/GYNs to understand
the complexity of hormones and to provide individualized hormone
optimization plans for both women and men. With the previous launch
of this new division dedicated to men’s health, Biote is continuing
to provide a deeper understanding of hormonal optimization to
practitioners in its network while building new partnerships with
urologists and internal medicine practitioners committed to helping
their male patients achieve optimal health.
About Biote
Biote is transforming healthy aging through innovative,
personalized hormone optimization therapies delivered by
Biote-certified medical providers. Biote trains practitioners how
to identify and treat early indicators of hormone-related aging
conditions, an underserved $7 billion global market, providing
affordable symptom relief for patients and driving clinic success
for practitioners.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Some of the forward-looking statements can be identified
by the use of forward-looking words. Statements that are not
historical in nature, including the words “may,” “can,” “should,”
“will,” “estimate,” “plan,” “project,” “forecast,” “intend,”
“expect,” “hope,” “anticipate,” “believe,” “seek,” “target,”
“continue,” “could,” “might,” “ongoing,” “potential,” “predict,”
“would” and other similar expressions, are intended to identify
forward-looking statements. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual results or developments to differ materially from
those expressed or implied by such forward-looking statements,
including but not limited to: the success of our dietary
supplements to attain significant market acceptance among clinics,
practitioners and their patients; our customers’ reliance on
certain third parties to support the manufacturing of bio-identical
hormones for prescribers; our and our customers’ sensitivity to
regulatory, economic, environmental and competitive conditions in
certain geographic regions; our ability to increase the use by
practitioners and clinics of the Biote Method at the rate that we
anticipate or at all; our ability to grow our business; the
significant competition we face in our industry; our limited
operating history; our ability to protect our intellectual
property; the heavy regulatory oversight in our industry; changes
in applicable laws or regulations; the inability to profitably
expand in existing markets and into new markets; the possibility
that we may be adversely impacted by other economic, business
and/or competitive factors, including recent bank failures; and
future exchange and interest rates. The foregoing list of factors
is not exhaustive. You should carefully consider the foregoing
factors and the other risks and uncertainties described in the
“Risk Factors” section of Biote’s Quarterly Report on Form 10-Q for
the fiscal quarter ended March 31, 2023 and other documents filed
by Biote from time to time with the Securities and Exchange
Commission. These filings identify and address other important
risks and uncertainties that could cause actual events and results
to differ materially from those contained in the forward-looking
statements. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and Biote assumes no obligation and
does not intend to update or revise these forward-looking
statements, whether as a result of new information, future events,
or otherwise. Biote does not give any assurance that it will
achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230622124901/en/
Press@biote.com
Biote (NASDAQ:BTMD)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Biote (NASDAQ:BTMD)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024